PODD is trading 6.1% up at $174.55 as investors reassess recent legal risks against the company's fundamental strength and upcoming earnings.
- The move follows a July 3, 2026, class action lawsuit regarding alleged Omnipod insulin under-delivery, which may be drawing bargain hunters back to the stock.
- Market sentiment is being bolstered by solid Q1 2026 results and anticipation for the upcoming Q2 earnings report scheduled for August 5, 2026.